このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Sirio Pharma 将来の成長

Future 基準チェック /36

Sirio Pharma利益と収益がそれぞれ年間22.1%と14.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に17.3% 21.9%なると予測されています。

主要情報

21.9%

収益成長率

21.7%

EPS成長率

Personal Products 収益成長	21.0%
収益成長率	14.4%
将来の株主資本利益率	17.4%
アナリストカバレッジ	Good
最終更新日	26 Sep 2024

今後の成長に関する最新情報

Recent updates

The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Sep 30

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Apr 24

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Mar 06

業績と収益の成長予測

SZSE:300791 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	5,758	584	N/A	856	4
12/31/2025	5,046	484	N/A	713	5
12/31/2024	4,356	393	N/A	588	5
6/30/2024	4,028	334	-82	361	N/A
3/31/2024	3,831	315	-155	276	N/A
12/31/2023	3,582	281	-66	386	N/A
9/30/2023	3,222	221	13	393	N/A
6/30/2023	2,941	204	64	370	N/A
3/31/2023	2,788	227	34	344	N/A
1/1/2023	2,507	212	151	445	N/A
9/30/2022	2,409	208	12	388	N/A
6/30/2022	2,315	196	-74	397	N/A
3/31/2022	2,283	189	-72	461	N/A
12/31/2021	2,369	232	-183	341	N/A
9/30/2021	2,361	272	-96	384	N/A
6/30/2021	2,316	279	-32	367	N/A
3/31/2021	2,216	265	-52	257	N/A
12/31/2020	2,067	257	96	320	N/A
9/30/2020	1,865	209	85	272	N/A
6/30/2020	1,710	178	40	203	N/A
3/31/2020	1,554	156	45	206	N/A
12/31/2019	1,580	143	65	232	N/A
9/30/2019	1,625	186	79	236	N/A
12/31/2018	1,595	203	-56	183	N/A
12/31/2017	1,330	104	N/A	49	N/A
12/31/2016	786	704	N/A	-98	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 300791の予測収益成長率 (年間22.1% ) は貯蓄率 ( 2.9% ) を上回っています。

収益対市場: 300791の収益 ( 21.8% ) CN市場 ( 22.5% ) よりも低い成長が予測されています。

高成長収益: 300791の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 300791の収益 ( 14.6% ) CN市場 ( 13.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: 300791の収益 ( 14.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 300791の自己資本利益率は、3年後には低くなると予測されています ( 17.3 %)。

Sirio Pharma 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Price target decreased by 7.2% to CN¥29.75

Price target increased by 7.8% to CN¥41.67

Consensus revenue estimates increase by 12%, EPS downgraded

Recent updates

The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Sirio Pharma Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 29%

Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Price target decreased by 7.2% to CN¥29.75

Second quarter 2024 earnings released: EPS: CN¥0.74 (vs CN¥0.30 in 2Q 2023)

Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Now 21% overvalued

Now 21% overvalued

Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Sirio Pharma Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Investor sentiment deteriorates as stock falls 27%

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Price target increased by 7.8% to CN¥41.67

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Sirio Pharma Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Sirio Pharma Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.37 in 3Q 2022)

Investor sentiment improves as stock rises 17%

Consensus revenue estimates increase by 12%, EPS downgraded

Second quarter 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.54 in 2Q 2022)

Sirio Pharma Co., Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Sirio Pharma Co., Ltd. Announces Implementation of Cash Dividend for the Year 2022, Payable on June 07, 2023

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.54 (vs CN¥0.49 in 2Q 2021)

Now 22% undervalued

Now 23% undervalued

Now 20% undervalued

Sirio Pharma Co., Ltd. announced that it expects to receive CNY 1.35 billion in funding

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces Final Profit Distribution Plan for 2021 on A Shares, Payable on 23 May 2022

Less than half of directors are independent

Sirio Pharma Co., Ltd., Annual General Meeting, May 05, 2022

Now 23% undervalued after recent price drop

Sirio Pharma Co., Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.34 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.41 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Sirio Pharma Co., Ltd. Approves Final Divided for 2020

Sirio Pharma Co., Ltd. Proposes Final Dividend for the Year 2020

Full year 2020 earnings released: EPS CN¥2.14 (vs CN¥1.46 in FY 2019)

New 90-day low: CN¥83.31

Investor sentiment deteriorated over the past week

New 90-day high: CN¥113

Investor sentiment improved over the past week

New 90-day low: CN¥84.38

New 90-day low: CN¥86.60

Third quarter earnings released

Market bids up stock over the past week

New 90-day high - CN¥116

Earnings released

Sirio Pharma Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥89.00

Sirio Pharma Co., Ltd. announced a financing transaction

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘